REFERENCES

REFERENCES

Ascherio, A., & Munger, K. L. (2016). Epidemiology of multiple sclerosis: From risk factors to prevention. Seminars in Neurology, 36(2), 103-114. https://doi.org/10.1055/s-0036-1579693 

Belbasis, L., Bellou, V., Evangelou, E., Ioannidis, J. P., & Tzoulaki, I. (2015). Environmental risk factors and multiple sclerosis: An umbrella review of systematic reviews and meta-analyses. The Lancet Neurology, 14(3), 263-273. https://doi.org/10.1016/S1474-4422(14)70267-4  

Boster, A., et al. (2020). "Biomarkers in multiple sclerosis: Where do we stand?" Current Neurology and Neuroscience Reports, 20(8), 32. https://doi.org/10.1007/s11910-020-01092-3 

Compston, A., & Coles, A. (2008). Multiple sclerosis. The Lancet, 372(9648), 1502-1517. https://doi.org/10.1016/S0140-6736(08)61620-7  

Cree, B. A., & Hauser, S. L. (2020). "Multiple sclerosis: New developments in diagnosis and management." JAMA, 324(10), 1029-1041. https://doi.org/10.1001/jama.2020.11345  

DeLuca, J., et al. (2018). "Cognitive rehabilitation in multiple sclerosis: A review." Neuropsychology Review, 28(1), 62-73. https://doi.org/10.1007/s11065-018-9377-4  

Dendrou, C. A., Fugger, L., & Friese, M. A. (2015). Immunopathology of multiple sclerosis. Nature Reviews Immunology, 15(9), 545-558. https://doi.org/10.1038/nri3871

Dobson, R., & Giovannoni, G. (2019). Multiple sclerosis – A review. European Journal of Neurology, 26(1), 27-40. https://doi.org/10.1111/ene.13819  

Filippi, M., Bar-Or, A., Piehl, F., Preziosa, P., Solari, A., Vukusic, S., & Rocca, M. A. (2018). Multiple sclerosis. Nature Reviews Disease Primers, 4(1), 43. https://doi.org/10.1038/s41572-018-0041-4 

Fisniku, L., et al. (2019). "Neuroprotective strategies in multiple sclerosis: focus on brain health." Nature Reviews Neurology, 15(1), 22-34. https://doi.org/10.1038/s41582-018-0085-0  

Gawande, A. (2014). The Checklist Manifesto: How to Get Things Right. Metropolitan Books. 

Roberts, E. (2017). Substance abuse and risk behavior: How addiction impacts safety. Journal of Addiction Medicine, 11(5), 387-399. 

Ghasemi, N., et al. (2017). "Multiple sclerosis: a review of its history, pathophysiology, and therapeutic strategies." Current Neuropharmacology, 15(3), 501-517. https://doi.org/10.2174/1570159X14666170317153504  

Goldenberg, M. M. (2012). "Multiple sclerosis review." P&T, 37(3), 175-184. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3298312/  

Hauser, S. L., & Cree, B. A. C. (2020). Multiple sclerosis: Relapse and progression. New England Journal of Medicine, 378(2), 169-180. https://doi.org/10.1056/NEJMra1515229  

Hauser, S. L., & Cree, B. A. (2020). Treatment of multiple sclerosis: A review. American Journal of Medicine, 133(12), 1380-1390. https://doi.org/10.1016/j.amjmed.2020.05.049  

Health and Safety Executive (HSE). (2021). Workplace safety standards: Reducing risk through protective gear and safety protocols. HSE Guidance Documents. Retrieved from https://www.hse.gov.uk  

Hedström, A. K., Olsson, T., & Alfredsson, L. (2016). Smoking and multiple sclerosis susceptibility. European Journal of Epidemiology, 31(10), 1-16. https://doi.org/10.1007/s10654-016-0143-6 

Hemmer, B., Kerschensteiner, M., & Korn, T. (2015). Role of the innate and adaptive immune responses in the course of multiple sclerosis. The Lancet Neurology, 14(4), 406-419. https://doi.org/10.1016/S1474-4422(14)70305-9 

Kalb, R. C., & Boudreau, A. (2020). MS rehabilitation. NeuroRehabilitation, 46(2), 167-178. https://doi.org/10.3233/NRE-192875  

Karpuk, D., & Filippini, N. (2020). "MS Research Directions: The Role of Imaging, Biomarkers, and Treatment Strategies." Frontiers in Neurology, 11, 179. https://doi.org/10.3389/fneur.2020.00179  

Koch-Henriksen, N., & Sørensen, P. S. (2010). "The changing demographic pattern of multiple sclerosis epidemiology." The Lancet Neurology, 9(5), 520-532. https://doi.org/10.1016/S1474-4422(10)70064-8  

Kuhlmann, T., et al. (2017). "Differential effects of sex on neuroinflammation in multiple sclerosis." Multiple Sclerosis Journal, 23(11), 1536-1547. https://doi.org/10.1177/1352458517708608  

Langer-Gould, A., et al. (2013). Incidence of multiple sclerosis in multiple racial and ethnic groups. Neurology, 80(19), 1734-1739. https://doi.org/10.1212/WNL.0b013e3182918cc2  

Lassmann, H., van Horssen, J., & Mahad, D. (2012). Progressive multiple sclerosis: Pathology and pathogenesis. Nature Reviews Neurology, 8(11), 647-656. https://doi.org/10.1038/nrneurol.2012.168 

Lassmann, H. (2018). Multiple sclerosis pathology. Cold Spring Harbor Perspectives in Medicine, 8(3), a028936. https://doi.org/10.1101/cshperspect.a028936   

Lublin, F. D., & Reingold, S. C. (2004). "Defining the clinical course of multiple sclerosis: results of the Consensus Conference." Neurology, 62(3), 508-512. https://doi.org/10.1212/01.WNL.0000108763.22803.0C  

Manouchehrinia, A., Hedström, A. K., Alfredsson, L., & Olsson, T. (2013). Association of pre-disease body mass index with multiple sclerosis prognosis. Neurology, 90(6), e420-e428. https://doi.org/10.1212/WNL.0000000000004917  

Montalban, X., et al. (2017). Ocrelizumab versus placebo in primary progressive multiple sclerosis. New England Journal of Medicine, 376(3), 209-220.  

Munger, K. L., Levin, L. I., Hollis, B. W., Howard, N. S., & Ascherio, A. (2006). Serum 25-hydroxyvitamin D levels and risk of multiple sclerosis. JAMA, 296(23), 2832-2838. https://doi.org/10.1001/jama.296.23.2832  

Munger, K. L., & Ascherio, A. (2011). "Risk factors in the onset of multiple sclerosis." Expert Review of Clinical Immunology, 7(5), 607-613. https://doi.org/10.1586/eci.11.50 

National Multiple Sclerosis Society. (2019). Prevalence of Multiple Sclerosis in the United States: A Population-Based Study. https://www.nationalmssociety.org/  

Olsson, T., Barcellos, L. F., & Alfredsson, L. (2017). "Interplay between genetic and environmental factors in the pathogenesis of multiple sclerosis." Nature Reviews Neurology, 13(1), 25-36. https://doi.org/10.1038/nrneurol.2016.187  

Phillips, K. (2024). Multiple Sclerosis [PowerPoint slides]. Department of Neuroscience, Virginia Tech. 

Pugliatti, M., et al. (2006). "The epidemiology of multiple sclerosis in Europe." European Journal of Neurology, 13(7), 700-722. https://doi.org/10.1111/j.1468-1331.2006.01342.x 

Reich, D. S., Lucchinetti, C. F., & Calabresi, P. A. (2018). Multiple sclerosis. New England Journal of Medicine, 378(2), 169-180. https://doi.org/10.1056/NEJMra1401483 

Ritchie, C. W., et al. (2019). "The gut-brain axis in multiple sclerosis: a review of the current evidence." Journal of Neuroinflammation, 16(1), 78. https://doi.org/10.1186/s12974-019-1500-5  

Sadiq, S. A. (2015). "Stem cell therapy for multiple sclerosis: Current approaches and future directions." Expert Opinion on Biological Therapy, 15(9), 1351-1363. https://doi.org/10.1517/14712598.2015.1042374  

Silva, A. S., & Andrade, A. C. (2020). Occupational risk factors for injury in contact sports. Sports Medicine Open, 6(1), 1-12. https://doi.org/10.1186/s40798-020-00275-8  

Thompson, A. J., Baranzini, S. E., Geurts, J., Hemmer, B., & Ciccarelli, O. (2018). Multiple sclerosis. The Lancet, 391(10130), 1622-1636. https://doi.org/10.1016/S0140-6736(18)30481-1  

Trapp, B. D., & Nave, K. A. (2008). Multiple sclerosis: An immune or neurodegenerative disorder? Annual Review of Neuroscience, 31, 247-269. https://doi.org/10.1146/annurev.neuro.30.051606.094313 

Tzeng, R. C., et al. (2019). "Neuroprotective strategies for multiple sclerosis." Neuroscience Bulletin, 35(4), 569-586. https://doi.org/10.1007/s12264-019-00353-0  

Wallin, M. T., et al. (2019). The prevalence of multiple sclerosis in the United States: A population-based estimate using health claims data. Neurology, 92(10), e1029-e1040. https://doi.org/10.1212/WNL.0000000000007035  

Westerhaus, M., & Zimmerman, C. (2016). Mental health and military service: Best practices and treatment outcomes. Journal of Military Medicine, 10(3), 197-207.  

IMAGES

Figure 1- Aetiology

Multiple Sclerosis Aetiology. (2024). Created using Microsoft Copilot with the prompt “Multiple Sclerosis Aetiology.”

Figure 2- Clinical Presentation

Multiple Sclerosis Clinical Presentation. (2024). Created using Microsoft Copilot with the prompt “Multiple Sclerosis Clinical Presentation.”

Figure 3- Treatments and Outlooks

Multiple Sclerosis Treatment and Outlooks. (2024). Created using Microsoft Copilot with the prompt “Multiple Sclerosis Treatment and Outlooks.”

Figure 4- Epidemiology

Multiple Sclerosis Epidemiology. (2024). Created using Microsoft Copilot with the prompt “Multiple Sclerosis Epidemiology.”

Figure 5- Looking Ahead

Multiple Sclerosis Looking Ahead. (2024). Created using Microsoft Copilot with the prompt “Multiple Sclerosis Looking Ahead.”